Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BLCM

Bellicum Pharmaceuticals (BLCM) Stock Price, News & Analysis

Bellicum Pharmaceuticals logo

About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.07
$0.09
50-Day Range
$0.07
$0.10
52-Week Range
$0.06
$1.31
Volume
6,059 shs
Average Volume
22,874 shs
Market Capitalization
$726,570.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

Remove Ads
Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BLCM Stock News Headlines

Urgent Bitcoin alert for RIGHT NOW
Former billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 40-year career. During the presentation, Larry reveals a strategy every trader and investor needs to understand. He calls it “Bitcoin Skimming.”
Bellicum Pharmaceuticals Inc BLCM
Futura Medical plc (FAMDF)
BLCM - Bellicum Pharmaceuticals, Inc.
See More Headlines

BLCM Stock Analysis - Frequently Asked Questions

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) announced its earnings results on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $1.15. The biopharmaceutical company earned $0.70 million during the quarter.

Bellicum Pharmaceuticals's stock reverse split on the morning of Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Bellicum Pharmaceuticals (BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), NVIDIA (NVDA), CyberArk Software (CYBR), Gilead Sciences (GILD) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
8/11/2021
Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BLCM
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,970,000.00
Pretax Margin
-1,492.40%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Price / Cash Flow
N/A
Book Value
$0.23 per share
Price / Book
0.33

Miscellaneous

Free Float
8,716,000
Market Cap
$726,570.00
Optionable
Not Optionable
Beta
1.39

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:BLCM) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners